Literature DB >> 1116389

Hemodynamic effects of edrophonium chloride (Tensilon) infusion.

J A Cooper, F Baratta, J Frieden, J Grossman.   

Abstract

The hemodynamic effects of a 10 mg bolus of edrophonium chloride followed by a continuous infusion of 0.25 to 1.0 mg per minute, were determined in unanesthetized patients with significant myocardial disease. The effect on heart rate of the drug was negated by studying a group of nine patients with complete heart block and permanently implanted ventricular pacemakers. After the 10 mg bolus, two of the nine patients experienced dizziness, nausea and abdominal cramps associated with a mild decrease in peripheral vascular resistance. There was no significant change in cardiac index, mean blood pressure, brachial artery upstroke time, corrected ejection time, or left ventricular systolic ejection time. This study demonstrated that the continuous infusion of 0.25 to 1.0 mg per minute of edrophonium chloride following a 10 mg loading dose, had no significant effect on myocardial function.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1116389     DOI: 10.1378/chest.67.2.147

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  3 in total

1.  Predominant Glandular Cholinergic Dysautonomia in Patients With Primary Sjögren's Syndrome.

Authors:  Richard Imrich; Ilias Alevizos; Lolita Bebris; David S Goldstein; Courtney S Holmes; Gabor G Illei; Nikolay P Nikolov
Journal:  Arthritis Rheumatol       Date:  2015-05       Impact factor: 10.995

2.  Intraoperative hemodynamic management for minimally invasive direct coronary artery bypass: two case reports.

Authors:  Seiji Watanabe; Takahiko Itou; Shinya Kaneko; Tadashi Isomura; Tatsuhiko Kano
Journal:  J Anesth       Date:  1998-03       Impact factor: 2.078

3.  Generalized and neurotransmitter-selective noradrenergic denervation in Parkinson's disease with orthostatic hypotension.

Authors:  Yehonatan Sharabi; Richard Imrich; Courtney Holmes; Sandra Pechnik; David S Goldstein
Journal:  Mov Disord       Date:  2008-09-15       Impact factor: 10.338

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.